HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GDC-0623

a Mapk-erk kinase inhibitor; structure in first source

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - GDC-0623: 2
  - Pyridines: 88
    - Nicotinic Acids: 13
      - Niacinamide: 2223
        GDC-0623: 2
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - Niacinamide: 2223
      - GDC-0623: 2

Experts

1.	Astete, Carlos E: 1 article (01/2020)
2.	Byrne, C Ethan: 1 article (01/2020)
3.	Knutson, Barbara L: 1 article (01/2020)
4.	Martin, Elizabeth C: 1 article (01/2020)
5.	Melvin, Adam T: 1 article (01/2020)
6.	Moradipour, Mahsa: 1 article (01/2020)
7.	Rankin, Stephen E: 1 article (01/2020)
8.	Sabliov, Cristina M: 1 article (01/2020)
9.	Vaithiyanathan, Manibarathi: 1 article (01/2020)
10.	Huang, Shengbing: 1 article (09/2015)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro."
2.	Colonic Neoplasms (Colon Cancer) 09/25/2015 - "GDC-0623 was shown to potently up-regulate BIM expression to a greater extent versus other MEK inhibitors in isogenic KRAS HCT116 and mutant KRAS SW620 colon cancer cells. "

Related Drugs and Biologics

1.	Mitogen-Activated Protein Kinase Kinases (MEKs)